Andrew Cook, MD, on On-Going Clinical Research Efforts in the Head and Neck Cancer Space

Video

CancerNetwork® sat down with Andrew Cook, MD, at the 2021 American Society for Radiation Oncology to discuss ongoing trials on treatment de-escalation and mitigating mucositis-related pain in head and neck cancer.

At the 2021 American Society for Radiation Oncology, CancerNetwork® spoke with Andrew Cook, MD, from Henry Ford Health System, about current ongoing trials in the head and neck cancer space, including efforts to better mitigate mucositis-related pain and treatment de-escalation.

Transcript:

At our specific institution, not myself, but some of my other colleagues are looking at an interesting question of what happens when you place an apparatus in a patient’s mouth to cool the oral mucosa while they’re undergoing radiation. [The intention is to] see if that may help to mitigate mucositis-related pain and improve quality of life going [for those] through treatments. That will be an exciting thing to see patients accrued on that and see what it may ultimately show. It’s an interesting idea. There are these other national trials looking at treatment deintensification of human papillomavirus positive oropharynx cancer, and those are going to be interesting. That's going to be a big direction of where the field is going.

Recent Videos
Trials at scale can be conducted in middle-income, low-middle-income, and even lower-income countries if you organize a trial ecosystem.
Immunotherapy-based combinations may elicit a synergistic effect that surpasses monotherapy outcomes among patients with muscle-invasive bladder cancer.
For example, you have a belt of certain diseases or genetic disorders that you come across, such as sickle cell disease or thalassemia, that are more prevalent in these areas.
Talent shortages in the manufacturing and administration of cellular therapies are problems that must be addressed at the level of each country.
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
Point-of-care manufacturing, scalable manufacturing, and bringing the cost down [can help].
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss presentations at ESMO 2025 that may impact bladder, kidney, and prostate cancer care.
Mandating additional immunotherapy infusions may help replenish T cells and enhance tumor penetration for solid tumors, including GI malignancies.
Related Content